Gelesis Holdings (Gelesis Holdings) 3-Year Book Growth Rate : 0.00% (As of Jun. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Gelesis Holdings 3-Year Book Growth Rate?

Gelesis Holdings's Book Value per Share for the quarter that ended in Jun. 2023 was $-0.43.

During the past 12 months, Gelesis Holdings's average Book Value per Share Growth Rate was -714.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Competitive Comparison of Gelesis Holdings's 3-Year Book Growth Rate

For the Biotechnology subindustry, Gelesis Holdings's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gelesis Holdings's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gelesis Holdings's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Gelesis Holdings's 3-Year Book Growth Rate falls into.

Gelesis Holdings 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Gelesis Holdings (OTCPK:GLSHQ) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Gelesis Holdings 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Gelesis Holdings's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Gelesis Holdings (Gelesis Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gelesis Holdings Inc (OTCPK:GLSHQ) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

501 Boylston Street, Suite 6102, Boston, MA, USA, 02116

Website

https://www.gelesis.com

Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.

Executives

Raju S Kucherlapati	director	77 LOUIS PASTEUR AVENUE, BOSTON MA 02115
Bomsmaster Llc	10 percent owner	195 CHURCH STREET, 15TH FLOOR, NEW HAVEN CT 06510
Paul R. Fonteyne	director	C/O RESTORBIO, INC., 501 BOYLSTON STREET SUITE 6102, BOSTON MA 02116
Hpso Spv Ltd	10 percent owner	SARNIA HOUSE, LE TRUCHOT, ST PETER PORT Y7 GY1 4NA
Alessandro Sannino	officer: Lead Project Scientist	C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Dominic Perks	director	GELESIS, INC., 501 BOYLSTON STREET, SUITE 1602, BOSTON NY 02116
David A. Pass	officer: Chief Op. & Comm. Officer	GELESIS, INC., 501 BOYLSTON STREET, SUITE 1602, BOSTON MA 02116
Elaine Chiquette	officer: Chief Scientific Officer	C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Jane Wildman	director	C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Harry L. Leider	officer: Chief Medical Officer	C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Clayton Christopher	director	2407 S. CONGRESS AVE, SUITE E103, AUSTIN TX 78704
Health Plc Puretech	10 percent owner	6 TIDE STREET, SUITE 400, BOSTON MA 02210
Ssd2, Llc	10 percent owner	142 TEMPLE STREET, SUITE 206, NEW HAVEN CT 06511
Yishai Zohar	director, officer: President & CEO	C/O GELESIS, INC., 501 BOYLSTON ST., SUITE 6102, BOSTON MA 02116
Elon Boms	10 percent owner	C/O THIMBLE POINT ACQUISITION CORP., 195 CHURCH STREET, 15TH FLOOR, NEW HAVEN CT 06510